Welcome to the e-CCO Library!

P279: Vedolizumab is safe for use in pregnant patients with IBD; report of our preliminary data
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Bar-Gil Shitrit1*, B. Koslowsky2, Y. Milgrom2, A. Lahat3, E. Goldin2, S. Granovsky- Grisaru4

Created: Thursday, 21 February 2019, 9:14 AM
P280 Sodium picosulfate low-volume and split-dosed bowel preparation facilitates endoscopic monitoring of patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Fasoulas, A. Katsimpeli, P. Kevrekidou, N. Kafalis, E. Stergiou, S. Bouzoukas, G. Lazaraki, D. Tzilves, K. Soufleris

Created: Thursday, 30 January 2020, 10:12 AM
P280: Endoscopic training leads to a significant increase in agreement of endoscopic scoring for inflammatory bowel disease: results of the IGIBDEndo educational project
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Daperno*1, M. Comberlato2, F. Bossa3, L. Biancone4, A. Bonanomi5, A. Cassinotti6, R. Cosintino7, R. Mangiarotti7, G. Lombardi8, A. Papa9, R. Pica10, M. Rabagliati11, L. Grassano11, M. Gasparini11, G. Pagana11, R. D’Incà12, A. Orlando13, F. Rizzello14

Created: Friday, 22 February 2019, 9:49 AM
P280: Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferrante, M.(1,2);Sabino, J.(1,2);Lobaton, T.(3);Dreesen, E.(4);Hoefkens, E.(5);Fierens, L.(2);Liefferinckx, C.(6);
Created: Wednesday, 2 June 2021, 4:12 PM
P280: Prediction factors for low bone mineral density in children with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Ronel1, A. Guz-Mark2, A. Assa2, R. Lev Zion1, E. Shteyer1, D. Strich1, D. Turner1, O. Ledder*1

Created: Friday, 22 February 2019, 9:41 AM
P280: Prognosis of patients with Crohns Disease in transmural remission with gastrointestinal ultrasound
Year: 2022
Source: ECCO'22
Authors: Nylund, K.(1);Sævik, F.(1);von Volkmann, H.L.(2);Gilja, O.H.(1);
Created: Friday, 11 February 2022, 3:52 PM
P280: Quality of life in military patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ben Safta, N.(1)*;Medhioub, A.(1);Mohamed, G.(1);Boughoula, K.(1);Ben Slimane, B.(1);Ben Abdallah, H.(1);Bouali, R.(1);Bizid, S.(1);Abdelli, M.N.(1);
Created: Friday, 14 July 2023, 11:05 AM
P280: Reducing the overprescribing of oral corticosteroids in IBD using a steroid assessment tool
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Scott1*, N. Roads1, W. Lewis2

Created: Thursday, 21 February 2019, 9:14 AM
P280: Therapeutic drug monitoring of infliximab and adalimumab for detection of patients at risk of loss of response in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gonzalez-Lopez J.1, Giráldez-Montero J.M.1, Ferreiro R.2, Lorenzo A.2, Lamas M.J.1, Dominguez-Munoz J.E.2, Barreiro-de Acosta M.*2

Created: Wednesday, 20 February 2019, 10:36 AM
P281 A serum biomarker panel can accurately identify the presence of mucosal ulcers in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. HOLMER, B. Boland, S. Singh, J. Neill, H. Le, A. Miralles, A. Collins, W. Sandborn, P. Dulai

Created: Thursday, 30 January 2020, 10:12 AM
P281: Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.-F. Colombel1*, C. Gasink2, A. Oortwijn3, R. van Kruchten3, S. Sloan2, V. Laliman4, P. Rutgeerts5, S. Ghosh6, W. Sandborn7, B. Feagan8, B. Sands1

Created: Thursday, 21 February 2019, 9:14 AM
P281: Conversion of the ileal pouch-anal anastomosis to a continent ileostomy – outcome and patient satisfaction
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hermanson, M.(1)*;Bengtson, J.(1);Block, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P281: Endoscopic healing assessed by advanced optical enhancement techniques combined with faecal calprotectin (FCP) can accurately assess histological healing in ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Cannatelli*1, U. N. Shivaji2,3, S. C. Smith1, D. Zardo4, A. Bazarova1, G. Gkoutos1, S. Ghosh1,2,3, M. Iacucci1,2,3,5

Created: Friday, 22 February 2019, 9:41 AM
P281: Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Deprez, N.(1);De Somer, T.(2);Baert, D.(2);Deceuninck, M.(3);Huys, I.(2);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten, E.(2);Vandervoort, J.(4);Vanheddegem, N.(2);Dewint, P.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P281: Factors at diagnosis associated with disabling disease course in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ponte A., Pinho R., Rodrigues A., Silva J., Rodrigues J., Sousa M., Silva A.P., Alberto L., Carvalho J.

Created: Wednesday, 20 February 2019, 10:36 AM
P281: One simple question is sufficient for measuring medication adherence in inflammatory bowel disease patients using self-report
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Severs*1, M.-J. Mangen2, H. H. Fidder1, M. E. van der Valk1, M. van der Have1, A. A. van Bodegraven3, 4, C. H. M. Clemens5, G. Dijkstra6, J. M. Jansen7, D. J. de Jong8, N. Mahmmod9, P. C. van de Meeberg10, A. E. van der Meulen- de Jong11, M. Pierik12, C. Y. Ponsioen13, M. J. L. Romberg- Camps3, P. D. Siersema1, J. R. Vermeijden14, J. van der Woude15, P. N. Zuithoff16, B. Oldenburg1

Created: Friday, 22 February 2019, 9:49 AM
P281: TELEIBD: A telematic fast-track pathway for patients with high suspicion of Inflammatory Bowel Disease in primary care.
Year: 2022
Source: ECCO'22
Authors: Pradera Cibreiro, C.(1);Ramos Alonso, M.(1);Fernández López, M.(1);Molina Arriero, G.(1);Fraga Iriso, R.(1);González Furelos, T.(1);Ollero Pena, V.(1);Echarri Piudo, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P282 Early disease acceleration in patients with newly diagnosed Crohn’s disease in India and Israel: Insights from an East-West inception cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Goren1, H. Yanai1, P. Pal2, B. Adigopula2, S. Pendyala2, G. Ganesh2, K. Yadgar1, R. Banerjee2, I. Dotan1, The Indo-Israeli IBD GastroEnterology paRtnership, ‘TiiiGER’ project

Created: Thursday, 30 January 2020, 10:12 AM
P282: Combination of biomarkers reflecting type IV collagen degradation and citrullinated vimentin predicts response to adalimumab with high diagnostic accuracy, in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. H. Mortensen*1, M. A. Karsdal1, H. Grønbæk2, C. L. Hvas2, A. Dige2, T. Manon-Jensen1

Created: Friday, 22 February 2019, 9:41 AM
P282: Despite surveillance and increased use of biologics and immunosuppressives colorectal cancer detection in IBD patients remains unchanged over the past ten years
Year: 2018
Source: ECCO '18 Vienna
Authors:

U.N. Shivaji1*, S.C.L. Smith1,2, R. Hejmadi3, T. Iqbal1, N. Bhala1, R. Cooney1, S. Ghosh1,2, M. Iacucci1,2

Created: Thursday, 21 February 2019, 9:14 AM